Our system provides the best of both worlds: development of new drugs and cheap options for most prescriptions. | Opinion ...

BOM is launching a venture-building programme in September to support entrepreneurs launching drug development startups.

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

The truth is simple: the “X” is not the problem. The real problem is a system that cannot stand to admit that people come in ...

One of Trump's demands was that the CEOs' companies limit drug costs for states' Medicaid plans to "most-favored nation" ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

The money will support dozens of different approaches for improving women’s health, from new medicines to prevent maternal ...

The prime minister fled. There's an interim government. Our writer urges global health groups, including WHO and UNICEF, to ...

Eli Lilly (NYSE: LLY) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding ...

Double-digit prescription gains for its commercial drugs, major coverage wins, and the early launch of a new migraine therapy were the most significant highlights. Despite substantial progress, the ...

Abivax, MapLight Therapeutics, Everest Medicines, and Soleno Therapeutics bagged the biggest biotech funding rounds overall ...

Scientists from UC San Francisco and the Gladstone Institutes have made a discovery that could offer new hope to people with ...